HPV status, particularly combined p16 and HPV positivity, is vital for patient selection in de-escalation strategies for ...
Experts explore evolving treatment strategies for head and neck squamous cell carcinoma, emphasizing biomarker analysis and ...
The dual inhibition of PD-1 and VEGF pathways by ivonescimab aims to enhance immune response and limit tumor angiogenesis, ...
In July 2025, a class 2 resubmission of tab-cel’s BLA was initiated by Atara Biotherapeutics, developer and sponsor of ...
TROPION-Lung17 will enroll approximately 400 patients across global sites. Participants are randomized 1:1 to receive either Dato-DXd (6.0 mg/kg intravenously every 3 weeks) or docetaxel (75 mg/m² ...
The phase 3 IMforte trial(NCT05091567) demonstrated benefit for expanding on maintenance immunotherapy in extensive-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback